Abbott Initiates Clinical Study To Evaluate Use Of RX Herculink(R) Elite(TM) Renal Stent System For The Treatment Of Renal Artery Stenosis
Abbott (NYSE: ABT) announced enrollment of the first patient in HERCULES (Herculink Elite Cobalt Chromium Renal Stent Trial to Demonstrate Efficacy and Safety), a U.S. clinical trial designed to evaluate the safety and effectiveness of the investigational RX Herculink(R) Elite(TM) Renal Stent System to treat patients with renal artery stenosis (RAS), a condition characterized by fatty plaque buildup in the kidney arteries that can lead to high blood pressure.
